Journal of Pharmacology and Experimental Therapeutics

Papers
(The H4-Index of Journal of Pharmacology and Experimental Therapeutics is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The Pharmacological Case for Cannabigerol109
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies99
Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy forμ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats58
Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes47
Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity46
Acetate, a Short-Chain Fatty Acid, Acutely Lowers Heart Rate and Cardiac Contractility Along with Blood Pressure40
Apigenin Ameliorates Insulin Resistance and Lipid Accumulation by Endoplasmic Reticulum Stress and SREBP-1c/SREBP-2 Pathway in Palmitate-Induced HepG2 Cells and High-Fat Diet–Fed Mice40
Different Antioxidative and Antiapoptotic Effects of Piceatannol and Resveratrol32
AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists32
Exosomal miR-145 and miR-885 Regulate Thrombosis in COVID-1930
Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein29
Methamphetamine Dysregulation of the Central Nervous System and Peripheral Immunity27
Stem Cell Therapies in Alzheimer’s Disease: Applications for Disease Modeling26
Therapeutic Effect of Neuraminidase-1–Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis26
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species an25
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease24
A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-622
The Role of microRNA in the Development, Diagnosis, and Treatment of Cardiovascular Disease: Recent Developments21
Transport Properties of Statins by Organic Anion Transporting Polypeptide 1A2 and Regulation by Transforming Growth Factor-β Signaling in Human Endothelial Cells21
COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels21
0.036366939544678